These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34101963)

  • 1. Intracellular Protein-Drug Interactions Probed by Direct Mass Spectrometry of Cell Lysates.
    Rogawski R; Rogel A; Bloch I; Gal M; Horovitz A; London N; Sharon M
    Angew Chem Int Ed Engl; 2021 Sep; 60(36):19637-19642. PubMed ID: 34101963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding protein-drug interactions using ion mobility-mass spectrometry.
    Eyers CE; Vonderach M; Ferries S; Jeacock K; Eyers PA
    Curr Opin Chem Biol; 2018 Feb; 42():167-176. PubMed ID: 29331721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solving the Competitive Binding Equilibria between Many Ligands: Application to High-Throughput Screening and Affinity Optimization.
    Blay V; Otero-Muras I; Annis DA
    Anal Chem; 2020 Sep; 92(18):12630-12638. PubMed ID: 32812419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput detection of drugs binding to proteins using desorption electrospray ionization mass spectrometry.
    Yao C; Na N; Huang L; He D; Ouyang J
    Anal Chim Acta; 2013 Sep; 794():60-6. PubMed ID: 23972976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug screening of pharmaceutical discovery compounds by micro-size exclusion chromatography/mass spectrometry.
    Wabnitz PA; Loo JA
    Rapid Commun Mass Spectrom; 2002; 16(2):85-91. PubMed ID: 11754252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass spectrometry-based methods for structural biology on a proteome-wide scale.
    Jones LM
    Biochem Soc Trans; 2020 Jun; 48(3):945-954. PubMed ID: 32412054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Native Mass Spectrometry in Fragment-Based Drug Discovery.
    Pedro L; Quinn RJ
    Molecules; 2016 Jul; 21(8):. PubMed ID: 27483215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-Resolved Acetaldehyde-Based Accessibility Profiling Maps Ligand-Target Interactions.
    Tian Y; Bao Q; Wang N; Wan N; Lv L; Hao H; He C; Ye H
    J Am Soc Mass Spectrom; 2021 Feb; 32(2):519-530. PubMed ID: 33382614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of the binding of small molecules to proteins by desorption electrospray ionization mass spectrometry combined with protein microarray.
    Yao C; Wang T; Zhang B; He D; Na N; Ouyang J
    J Am Soc Mass Spectrom; 2015 Nov; 26(11):1950-8. PubMed ID: 26174365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures.
    Annis DA; Nazef N; Chuang CC; Scott MP; Nash HM
    J Am Chem Soc; 2004 Dec; 126(47):15495-503. PubMed ID: 15563178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of drug-protein interactions by capillary electrophoresis hyphenated to mass spectrometry.
    Vuignier K; Veuthey JL; Carrupt PA; Schappler J
    Electrophoresis; 2012 Nov; 33(22):3306-15. PubMed ID: 22949263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of DNA/Ligand interactions by electrospray ionization mass spectrometry.
    Brodbelt JS
    Annu Rev Anal Chem (Palo Alto Calif); 2010; 3():67-87. PubMed ID: 20636034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ion mobility-mass spectrometry of intact protein--ligand complexes for pharmaceutical drug discovery and development.
    Niu S; Rabuck JN; Ruotolo BT
    Curr Opin Chem Biol; 2013 Oct; 17(5):809-17. PubMed ID: 23856053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the Exactive Plus EMR for automated protein-ligand screening by non-covalent mass spectrometry.
    Maple HJ; Scheibner O; Baumert M; Allen M; Taylor RJ; Garlish RA; Bromirski M; Burnley RJ
    Rapid Commun Mass Spectrom; 2014 Jul; 28(13):1561-8. PubMed ID: 24861608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The application of MALDI TOF MS in biopharmaceutical research.
    Kafka AP; Kleffmann T; Rades T; McDowell A
    Int J Pharm; 2011 Sep; 417(1-2):70-82. PubMed ID: 21147205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct analysis in real time--high resolution mass spectrometry as a valuable tool for the pharmaceutical drug development.
    Srbek J; Klejdus B; Douša M; Břicháč J; Stasiak P; Reitmajer J; Nováková L
    Talanta; 2014 Dec; 130():518-26. PubMed ID: 25159441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Label-free screening assays: a strategy for finding better drug candidates.
    Lunn CA
    Future Med Chem; 2010 Nov; 2(11):1703-16. PubMed ID: 21428840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoproteomics: Towards Global Drug Target Profiling.
    Lu KY
    Chembiochem; 2020 Nov; 21(22):3189-3191. PubMed ID: 32935403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lead discovery for mammalian elongation of long chain fatty acids family 6 using a combination of high-throughput fluorescent-based assay and RapidFire mass spectrometry assay.
    Takamiya M; Sakurai M; Teranishi F; Ikeda T; Kamiyama T; Asai A
    Biochem Biophys Res Commun; 2016 Nov; 480(4):721-726. PubMed ID: 27793673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studying protein-protein affinity and immobilized ligand-protein affinity interactions using MS-based methods.
    Kool J; Jonker N; Irth H; Niessen WM
    Anal Bioanal Chem; 2011 Sep; 401(4):1109-25. PubMed ID: 21755271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.